This site is intended for health professionals only

EC approves sodium oxybate treating narcolepsy with cataplexy in adults


According to a report by Pharmalive, the European Commission has approved sodium oxybate (Xyrem®) for treating narcolepsy with cataplexy in adult patients.

Narcolepsy is a disorder which typically begins with excessive daytime sleepiness during the second and third decades of life, progressing to include disturbed night-time sleep, cataplexy, sleep paralysis and hypnagogic hallucinations (hallucinations while falling asleep).

The most commonly reported adverse drug reactions with sodium oxybate are dizziness, nausea, and headache, all occurring in 10% to 20% of patients.

National Electronic Library for Medicines 13/03/2007

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine